Clinical Trials

At Blueberry Therapeutics

Clinical Trial Icon

Blueberry Therapeutics Ongoing and Completed Clinical Trials

Multi-centre, international, randomised, vehicle controlled, parallel-group, double-blinded Phase 2 trial of BB2603 topical treatment in subjects with distal subungual onychomycosis (DSO) of the toenail (BBTAF202).Trial BBTAF202 is actively recruiting patients in Europe ( identifier NCT04188574, EudraCT identifier 2019-002098-68).
Click here for information on this clinical trial.
Early phase development, partly blinded, positive and vehicle controlled, randomised, non-inferiority investigation of the pharmacokinetics, safety
and efficacy of BB2603 cutaneous
hand-pump spray versus Lamisil®
spray and versus BB2603 vehicle
hand-pump spray in subjects with onychomycosis and associated tinea pedis (BBT120126032001)
Trial BBT120126032001 has completed (EudraCT identifier 2016-001242-25).
Click here for information on this clinical trial.

Drugs in our pipeline
Patents and exclusives licences
Billion dollars in commercial potential

Blueberry Therapeutics Ltd Blueberry Therapeutics, Mereside, Alderley Park,
Alderley Edge, Cheshire, SK10 4TG.